Belgian biopharmaceutical company UCB has partnered with Harvard University researchers to study the species found in the human microbiome -- the bacteria living inside the human body -- and how they affect the body's immune system. The objective of the UCB-funded project is to discover new drugs for preventing or treating immunological disorders. "We hope this project will fundamentally shift the paradigm of drug development for immunological diseases, exploiting naturally occurring molecules evolutionarily designed to thwart or harness the immune system," Harvard researchers said.

Related Summaries